MML Investors Services
MCRB icon

MML Investors Services’s Seres Therapeutics MCRB Stock Holding History

MML Investors Services’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-793
Closed -$11K – 2851
2025
Q1 		$11K Hold
793
– – ﹤0.01% 2679
2024
Q4 		$13K Buy
793
+49
+7% +$796 ﹤0.01% 2654
2024
Q3 		$14K Hold
744
– – ﹤0.01% 2562
2024
Q2 		$11K Hold
744
– – ﹤0.01% 2466
2024
Q1 		$12K Buy
+744
New +$16K ﹤0.01% 2462

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

MML Investors Services's MCRB Position: Q2 2025 in Review

MML Investors Services sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 793 shares — an estimated $11K sold.

MML Investors Services first reported a position in MCRB in Q1 2024 and held it in 5 quarters. The position peaked at $14K in Q3 2024. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • MML Investors Services reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • MML Investors Services sold 793 Seres Therapeutics shares in Q2 2025, an estimated $11K.
  • MML Investors Services first reported a position in Seres Therapeutics in Q1 2024 and held it in 5 quarters.
  • MML Investors Services's Seres Therapeutics position peaked at $14K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on MML Investors Services's 13F filing for Q2 2025, filed 14 Aug 2025.